GlassScriptPhysician profile
Lananh T DO
NPI 1235247966
$12,420.29
in general payments reported to CMS, 2019-2025
37 companies · $2,282 in 2025
The $2,282 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,145 · 2020: $812 · 2021: $1,135 · 2022: $2,461 · 2023: $1,692 · 2024: $1,893 · 2025: $2,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,867.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,400.40 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,302.76 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,296.11 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,010.69 | 2019-2025 | Dupixent |
| Amgen INC. | $774.47 | 2022-2025 | Tezspire, Actimmune |
| Novartis Pharmaceuticals Corporation | $713.88 | 2019-2025 | |
| Csl Behring | $595.18 | 2019-2025 | Hizentra |
| Pfizer INC. | $540.81 | 2019-2025 | |
| Genentech USA, INC. | $496.24 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $471.76 | 2020-2025 | Cinryze, Cuvitru, Takhzyro |
| Optinose US, INC. | $304.70 | 2019-2024 | |
| Grifols USA, LLC | $304.26 | 2019-2025 | Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.60 | 2019-2021 | |
| Alk-Abello, INC | $225.83 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Octapharma USA, INC. | $218.70 | 2019-2024 | Cutaquig |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lananh DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.